Evidence item

The primary trial report gives the disease-control rate as 95% among 40 participants. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 18930

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:3bb41b5b0e9b2ae91874b4ad7576efb2c763ff5ef684f081746f6686e5eedb1e

Exact excerpt

Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial responses among 40 participants) and a disease control rate of 95% (95% CI 83.5–99.4); the median duration of response was 12.6 months (95% CI 5.7–not reached).

Linked claims

Claim	Direction	Relevance	Steps	Counted
55e55a0b	SUPPORT	DIRECT	0	yes

Audits

None.